Assessment of Clin. Capabilities of LIBERTY® Endovascular Robotic System's Performance & Safety in Periph. Vasc. Interv.

Inclusion criteria

• The subject is age 22-80 years at screening.
• The subject has been informed of the nature of the study and is willing and able to provide informed consent to participate in the study.
• The subject has a clinical indication for an elective PVI.
• The subject is willing and able to comply with all required study procedures.
• Subject's scheduled procedure is compatible with commercially available peripheral interventional devices that have the following diameter ranges:

• Guidewires: 0.014-0.018"
• Catheters (Microcatheters): 2-3 Fr
• Guide catheter: 4-6 Fr

Exclusion criteria

• Subject is planned to undergo coronary and/or neuro-interventional procedures during study procedure.
• Subject with vasculature that cannot accommodate the catheter or required accessories according to local routine practice guidelines.
• Subject with contraindication to endovascular approach to the treatment of peripheral vascular disease, similar or same as contraindications in manual procedures.
• Target vessel has been previously treated with any type of a bypass conduit.
• Subject has a contraindication to standard anticoagulation for PVIs.
• Subject has bleeding or a hypercoagulability disorder.
• Subject has thrombocytopenia (<50 x103 per µL).
• Subject has abnormal, clinically relevant lab results resulting in treatment and/or increased risk to the subject.
• Subject has an elevated serum creatinine (≥2.5 mg/dL or ≥221 mmol/L).
• Subject has an active infection requiring antibiotic or anti-fungal systemic treatment.
• Subject has a known allergy to any material used or any component of the devices used that will be in direct contact with subject's tissue.
• Subject is pregnant or lactating.
• Subject with any medical, social, or psychological conditions which, in the opinion of the investigator, would prohibit appropriate consent or impair completion of the study protocol or study procedures.
• Subject who is incapable, per the investigator's discretion, of following-up with the study visit schedule for any reason.
• Subject is currently participating in an investigational drug or device study or post market registry, or participated in another investigational drug or device study within one month prior to enrollment.